Breathe Well Live Well
|
Asthma and COPD Therapies: World Market 2013-2023
MarketWatch You see why the asthma and COPD market will grow, as we predict. In our investigation you find revenue forecasting, growth rates and market shares. Also, you see qualitative analyses, R&D and commercial developments. You receive 114 tables, 210 charts … Prominent issues affecting the asthma and COPD market |
View full post on asthma – Google News
|
Do Asthmatic Children Grow Into Adults With COPD?
Medscape From a survey of 30,000 children aged 7 years, a group of 479 children with asthma (as defined by a questionnaire) and a control group similar to the asthmatic children were enrolled. The groups were followed with clinical evaluations, questionnaires … |
View full post on asthma – Google News
Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: Mepolizumab; Drug: Placebo
Sponsor: GlaxoSmithKline
Not yet recruiting – verified April 2014
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
|
Teva snags an EU recommendation for its asthma, COPD inhaler
FierceDrugDelivery European regulatory authorities gave Teva ($TEVA) a positive opinion for its DuoResp Spiromax inhalation powder, designed to treat asthma and chronic obstructive pulmonary disease (COPD). With the recommendation from the Committee for Medicinal … |
View full post on asthma – Google News
|
Teva's DuoResp Spiromax gets positive CHMP opinion to treat asthma and COPD
Pharmaceutical Business Review DuoResp Spiromax is a new multi-dose dry-powder inhaler with a combination of budesonide, an inhaled corticosteroid for the treatment of underlying inflammation in asthma and COPD, and formoterol fumarate dihydrate, a rapid-acting and long-lasting … Teva's Symbicort generic backed for EU approval 10 new medicines recommended for approval in Europe |
View full post on asthma – Google News
Conditions: Asthma; COPD
Intervention:
Sponsor: Medical University of Warsaw
Recruiting – verified February 2014
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
|
EU Panel Recommends Approval for 6 COPD, Asthma Drugs
Medscape The 2 drugs receiving a positive CHMP opinion for treatment of adults with asthma and COPD are the combination of the inhaled corticosteroid budesonide and the long-acting ?2 agonist formoterol, under the brand names of DuoResp Spiromax and BiResp … GSK lung drug Anoro recommended for European approval EU Agency backs respiratory drugs for approval GSK share price: Pharma giant closes in on another COPD drug approval in … |
View full post on asthma – Google News
Conditions: Pulmonary Disease, Chronic Obstructive; Asthma
Interventions: Drug: LAS190792 Dose 1; Drug: LAS190792 Dose 2; Drug: LAS190792 Dose 3; Drug: LAS190792 Dose 4; Drug: LAS190792 Dose 5; Drug: LAS190792 Dose 6; Drug: LAS190792 Dose 1 (Part 2); Drug: LAS190792 Dose 2 (Part 2); Drug: Tiotropium 18 ?g; Drug: Indacaterol 150 ?g; Drug: Placebo
Sponsor: Almirall, S.A.
Recruiting – verified February 2014
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
Conditions: Asthma; COPD
Intervention:
Sponsor: Elpen Pharmaceutical Co. Inc.
Not yet recruiting – verified January 2014
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
|
New class of drug shows promise for treating asthma and COPD
YottaFire Scientists have developed a new drug (RPL554) that could treat obstructive airway diseases such as asthma and chronic obstructive pulmonary disease (COPD) in two ways at once, according to new research published in The Lancet Respiratory Medicine. |
View full post on asthma – Google News